Should the ticagrelor (Brilinta) dose be reduced to 60 mg twice daily in a patient with in‑stent restenosis?

Ticagrelor Dosing in In-Stent Restenosis

No, do not lower ticagrelor to 60 mg twice daily in a patient with in-stent restenosis—maintain the standard 90 mg twice daily dose. In-stent restenosis represents a high ischemic risk scenario requiring potent platelet inhibition, and the 60 mg dose is specifically indicated only for long-term secondary prevention (>1 year post-MI) in stable patients, not for acute or high-risk thrombotic situations.

Rationale for Standard Dosing

The 2025 ACC/AHA guidelines clearly specify that ticagrelor 90 mg twice daily is the recommended maintenance dose for acute coronary syndromes and post-PCI patients. 1 The dosing table explicitly states: "Loading dose 180 mg orally, Maintenance dose 90 mg orally twice daily" for NSTE-ACS or STEMI without fibrinolytic therapy. 1

When 60 mg Dosing Is Appropriate

The FDA-approved 60 mg twice daily dose has a very specific indication: "After one year, administer 60 mg twice daily" in patients with a history of MI who have completed the initial 12 months of treatment. 2 This lower dose is for:

• Long-term secondary prevention in stable patients with prior MI (>1 year ago) 2
• Patients with established CAD and no prior stroke or MI 2
• Extended DAPT beyond the first year when ischemic risk remains elevated but the acute phase has passed 3

Why In-Stent Restenosis Requires Standard Dosing

In-stent restenosis is a high-risk thrombotic scenario that demands maximal platelet inhibition. 4 Research demonstrates that:

• Ticagrelor 90 mg twice daily effectively overcomes high platelet reactivity in patients with coronary artery in-stent restenosis, achieving significantly lower platelet reactivity (44.38±40.26 PRU) compared to high-dose clopidogrel (212.58±52.34 PRU). 4
• No patients receiving standard-dose ticagrelor exhibited high on-treatment platelet reactivity in the ISR population, whereas 62.5% remained with HTPR on high-dose clopidogrel. 4
• The first 12 months post-PCI carries the highest risk for major adverse cardiovascular events and stent thrombosis, necessitating potent P2Y12 inhibition. 1, 5

Clinical Algorithm for Ticagrelor Dosing

Initial Phase (0-12 months post-PCI or during ACS):

• Loading dose: 180 mg orally 1
• Maintenance: 90 mg twice daily 1
• This applies to all ACS patients, including those with in-stent restenosis 1, 4

Extended Phase (>12 months post-MI in stable patients):

• Consider reduction to 60 mg twice daily only if:
  • Patient is >1 year post-MI 2
  • Patient is clinically stable (no recent ACS or revascularization) 3
  • High ischemic risk features persist (diabetes, multivessel CAD, PAD, prior MI) 1
  • No high bleeding risk 1

Important Caveats

Aspirin dosing matters with ticagrelor: Use low-dose aspirin (75-100 mg daily, preferably 81 mg) with ticagrelor, as higher aspirin doses (>100 mg) were associated with worse outcomes in the PLATO trial. 1

Bleeding risk considerations: While the 60 mg dose was developed partly to reduce bleeding risk in long-term therapy 6, 3, switching to this lower dose during an acute high-risk period (like ISR management) would inappropriately prioritize bleeding avoidance over thrombotic protection when the latter is paramount. 4

Pharmacodynamic data supports this approach: The 60 mg dose achieves adequate platelet inhibition in stable patients 6, but the 90 mg dose provides more consistent and potent inhibition with less variability—critical when managing acute thrombotic risk. 7, 6